AcelRx Pharmaceuticals Company Profile (NASDAQ:ACRX)

Analyst Ratings

Consensus Ratings for AcelRx Pharmaceuticals (NASDAQ:ACRX) (?)
Ratings Breakdown: 2 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $7.63 (147.56% upside)

Analysts' Ratings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Seaport Global SecuritiesUpgradeAccumulate -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016HC WainwrightReiterated RatingBuy$9.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2016Janney Montgomery ScottInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015Royal Bank Of CanadaLower Price Target$7.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2015MizuhoReiterated RatingNeutral$5.50 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2015JMP SecuritiesLower Price TargetMarket Outperform$12.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2015Canaccord GenuitySet Price TargetHold$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/29/2014Piper Jaffray Cos.DowngradeOverweight -> Neutral$14.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/1/2016        
7/28/2016Q216($0.22)($0.24)$2.17 million$4.53 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2016Q1($0.20)($0.24)$1.62 million$1.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2016Q415($0.10)($0.24)$4.97 million$1.73 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/29/2015Q315($0.23)$0.11$1.75 million$13.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2015Q215($0.26)($0.20)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q115($0.28)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2015($0.33)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.26)($0.24)$40.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.23)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014Q413($0.17)($0.18)$4.93 million$27.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.19)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2013Q2 2013($0.22)($0.22)$1.73 million$0.41 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.38)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.31)($0.19)($0.25)
Q2 20162($0.28)($0.23)($0.26)
Q3 20162($0.28)($0.22)($0.25)
Q4 20162($0.23)($0.23)($0.23)
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.24)($0.24)($0.24)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/13/2016Howard B RosenCEOBuy10,206$3.26$33,271.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Mark G EdwardsDirectorBuy15,000$3.15$47,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2015Perceptive Advisors LlcMajor ShareholderSell176,200$5.35$942,670.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/6/2015Perceptive Advisors LlcMajor ShareholderSell92,100$4.59$422,739.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2015Perceptive Advisors LlcMajor ShareholderSell310,000$4.18$1,295,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2015Mark G EdwardsDirectorBuy40,000$3.13$125,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2014Mark WanDirectorSell1,000,000$12.35$12,350,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/7/2013Perceptive Advisors Llcmajor shareholderBuy200,000$6.51$1,302,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2013Perceptive Advisors Llcmajor shareholderBuy155,000$6.87$1,064,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/1/2013Perceptive Advisors LlcMajor ShareholderBuy360,660$6.91$2,492,160.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/20/2013Guy NohraDirectorSell158,153$10.59$1,674,840.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2013Guy NohraDirectorSell128,780$10.42$1,341,887.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013Perceptive Advisors LlcMajor ShareholderBuy850,000$11.65$9,902,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2013Mark G EdwardsDirectorBuy10,000$8.10$81,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013Adrian AdamsDirectorBuy75,000$8.19$614,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2012Mark A WanDirectorBuy2,416,918$3.31$7,999,998.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AcelRx Pharmaceuticals (NASDAQ:ACRX)
DateHeadline
07/28/16 08:30 PMAcelRx Pharmaceuticals : Provides Corporate Update and Reports Second Quarter and Six Months 2016 Financial Results
07/28/16 05:17 PMAcelRx Pharmaceuticals reports 2Q loss -
07/28/16 06:07 AMQ2 2016 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close -
07/26/16 11:09 AMAcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, …
07/26/16 06:00 AMAcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Thursday, July 28th, 2016 - [PR Newswire] - REDWOOD CITY, Calif., July 26, 2016 /PRNewswire/-- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain today announced that it will release Second Quarter financial results after market close on Thursday, July 28th, 2016. The FDA has requested an additional clinical study (IAP312), which AcelRx is planning to initiate in 2016, to support resubmission of the NDA.
07/23/16 07:52 AMIs $11.25 Price Target Attainable For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)? - Investor Newswire
07/20/16 02:34 PMEquity Roundup: Stock Performance Focus on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
07/20/16 02:34 PMCan AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Keep Up with Analyst Expectations? - Investor Newswire
07/20/16 11:05 AMETF’s with exposure to AcelRx Pharmaceuticals, Inc. : July 20, 2016 -
07/19/16 08:29 AMEarnings Focus and Crowd Sourced Sentiment Review for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - TGP
07/19/16 08:29 AMAcelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) Shorted Shares Increased By 30.92% - Press Telegraph
07/18/16 02:17 PMAcelRx Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News
07/16/16 02:17 PMHow Analysts Rated AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Last Week? - Press Telegraph
07/14/16 02:17 PMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 11:09 AMInsiders Increasing Positions in: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
07/14/16 11:09 AMAnalyst Target and Average Rating Watch: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
07/13/16 02:19 PMAcelrx Pharmaceuticals Incorporated (NASDAQ:ACRX) Sellers Covered 2.85% of Their Shorts - Consumer Eagle
07/13/16 02:19 PMIs Selling AcelRx Pharmaceuticals Inc Here a Winning Strategy? The Stock Formed Bearish Wedge Down - Consumer Eagle
07/12/16 07:45 PMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 02:17 PMShares Charging Upward in Session: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Telanagana Press
07/10/16 07:04 AMNext Weeks Broker Price Targets For AcelRx Pharmaceuticals, Inc. (ACRX) - Fiscal Standard
07/08/16 07:28 PMIs $11.25 Within Reach For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)? - Investor Newswire
07/08/16 02:18 PMIncreased Volatility on Shares of: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Engelwood Daily
07/08/16 05:09 AMACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
07/07/16 10:12 AMCompany Stock Focus for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX): Which Way Will Shares Head? - Press Telegraph
07/06/16 02:17 PMIncreased Volatility Watch for: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Engelwood Daily
07/06/16 07:03 AMBroker Outlook For AcelRx Pharmaceuticals, Inc. (ACRX) - Fiscal Standard
07/06/16 06:00 AMAcelRx Pharmaceuticals to Present at Cantor Fitzgerald 2nd Annual Healthcare Conference - [PR Newswire] - REDWOOD CITY, Calif., July 6, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that Chief Executive Officer, Howard Rosen will be presenting at the Cantor Fitzgerald 2nd Annual Healthcare Conference. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain.
07/04/16 02:16 PMShare Performance Recap for: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
07/04/16 07:04 AMBroker Outlook For The Week Ahead AcelRx Pharmaceuticals, Inc. (ACRX) - Fiscal Standard
07/02/16 09:59 AMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Expected to Reach Highs Of $11.25 - Investor Newswire
07/01/16 02:17 PMAre Analysts Bearish AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) After Last Week? - Engelwood Daily
06/30/16 07:44 PMAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Earnings Glance and Target Price Review - Engelwood Daily
06/30/16 02:17 PMUpdate on Stock Volatility for: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Engelwood Daily
06/30/16 02:17 PMAcelRx Pharmaceuticals Inc. (ACRX) Jumps 8% on June 29 - Equities.com
06/30/16 02:17 PMAcelRx Pharmaceuticals Inc. (ACRX) Hits New 52-week Low During June 28 Session - Equities.com
06/30/16 10:10 AMAcelRx Pharmaceuticals : Pharma (ACRX) Completes Enrollment in Remaining ARX-04 Phase 3s
06/29/16 02:17 PMRecently Issued Stock Ratings For AcelRx Pharmaceuticals, Inc. (ACRX) - Fiscal Standard
06/28/16 07:15 AMCompany Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Completes Patient Enrollment in Remaining Phase 3 ... - Smarter Analyst
06/28/16 06:00 AMAcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain - [PR Newswire] - SAP302 is a single-arm, open-label study that enrolled 76 adult patients who presented in the emergency room with moderate-to-severe acute pain associated with trauma or injury. SAP303 is a multicenter, open-label study that enrolled 139 patients 40 years and older who had moderate-to-severe acute pain following a surgical procedure with general anesthesia or spinal anesthesia (except those who received intrathecal opioids).
06/27/16 02:27 PMToday's Watch List: Spherix Incorporated (NASDAQ:SPEX), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), Agilent ... - KC Register
06/27/16 02:27 PMShares in Oversold Area: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
06/27/16 02:27 PMStock Touching a Recent Low: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
06/27/16 02:27 PMStock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Joins Russell 3000 and Russell 2000 Indexes - Smarter Analyst
06/27/16 06:00 AMAcelRx Pharmaceuticals Joins Russell 3000 and Russell 2000 Indexes - [PR Newswire] - REDWOOD CITY, Calif., June 27, 2016 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today announced that the company has joined the broad-market Russell 3000 and Russell 2000 Indexes according to the final membership lists posted June 24th, 2016. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10% of the total market capitalization of that index. Membership in the Russell 3000® Index includes automatic inclusion in the appropriate growth and style indexes.
06/25/16 10:04 AMStrong Sell Calls Recommendations For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) At 0 - Investor Newswire
06/25/16 10:04 AMAnalyst's Stocks Ratings Trend: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) , Alimera Sciences, Inc. (NASDAQ:ALIM) - Street Updates
06/24/16 02:17 PMShares Dropping to a Recent Low: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Press Telegraph
06/24/16 10:22 AMNew Broker Ratings For AcelRx Pharmaceuticals, Inc. (ACRX) - FTSE News
06/24/16 10:22 AMAcelRx Pharmaceuticals Inc. (ACRX) Drops 5.23% on June 22 - Equities.com

Social

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals logoAcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACRX
  • CUSIP:
Key Metrics:
  • Previous Close: $3.08
  • 50 Day Moving Average: $2.91
  • 200 Day Moving Average: $3.30
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $139.56M
  • Beta: 2.16
  • Current Year EPS Consensus Estimate: $-0.89 EPS
  • Next Year EPS Consensus Estimate: $-0.88 EPS
Additional Links:
AcelRx Pharmaceuticals (NASDAQ:ACRX) Chart for Friday, July, 29, 2016